Abstract 1502P
Background
Rectal cancer treatments have improved significantly over the past two decades, leading to higher survival rates. However, there's a growing emphasis on the long-term quality of life for survivors, including addressing sexual health needs. Our study aims to evaluate QOL, particularly sexual dysfunction, using validated tools like EORTC QLQ-C30, QLQ-CR29, and GRISS, aiming to improve care for rectal cancer patients.
Methods
Validated questionnaires (EORTC QLQ-C30, QLQ-CR29, GRISS) were completed by participants, assessing various aspects of quality of life and sexual satisfaction. Statistical analyses included tests for normality, descriptive analyses of patient characteristics, correlation analyses between questionnaire scores, and comparison of median scores using appropriate tests.
Results
The study included a total of 83 participants. Mean age of 55.95 ± 11.53, predominantly under 65 years (79.5%). A majority of patients (65.1%) had a stoma, and 78.3% underwent surgery, with 67.5% retaining sphincter function. The cohort was divided into non-metastatic (60.2%) and metastatic (39.8%) groups Significant correlations were observed between the Golombok Total Score and various subscores of the C30 scale. The fatigue subscore correlated positively with Golombok-female Total Score (r=0.331, p=0.041) and Golombok-male Total Score (r=0.370, p=0.042). Body image (p
Conclusions
This study demonstrates the profound and varied impact of rectal cancer treatment on patients' sexual health and overall quality of life, particularly affected by the presence of a stoma and metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10